Assertio Holdings Reports Departure of Chief Commercial Officer

Assertio Holdings Inc. reported the departure of its chief commercial officer, effective May 7, 2026.

The 8-K filing lists Item 5.02, Departure of Directors or Certain Officers. It identifies the named executive but does not disclose the individual's name in the structured summary or cite a specific cause for the departure. The filing also covers Item 5.07 on the submission of matters to a vote of security holders and Item 9.01 on financial statements and exhibits.

The departure affects the company's commercial leadership, which oversees sales, marketing, and distribution functions for its portfolio of pharmaceutical products. Assertio Holdings, with CIK 0001808665 and ticker ASRT, is a public company whose commercial officer directly influences revenue generation from its specialty drug offerings.

No dollar amounts or percentages tied to the role appear in the filing.

The operational change removes the prior chief commercial officer from the executive roster immediately. The new state leaves the position vacant until the board elects a replacement or assigns interim responsibilities. Standard SEC rules require the company to amend disclosures or file a subsequent 8-K if a successor is named within the four-business-day reporting window or to explain the absence of a named replacement.

Downstream, the departure obliges the company to update its executive compensation and governance disclosures in its next proxy statement or Form 10-K. It also starts the clock for any contractual severance or release agreements that must be reported under Item 5.02 if material.

The board of directors must now determine whether to conduct an external search or reallocate duties among remaining officers, actions that in turn affect the timing of any future executive-compensation amendments filed with the SEC.

This filing marks the latest executive transition recorded by Assertio Holdings in its SEC reporting history. The company has previously used Form 8-K to document officer changes under Item 5.02, a standard requirement for public companies under Section 13 or 15(d) of the Securities Exchange Act.